StageSeries A - III | Alive
Last Raised$20M | 2 yrs ago
About 858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecules directed against novel therapeutic targets in oncology such as proteins that regulate RNA and the innate immune response.
Missing: 858 Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: 858 Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing 858 Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
858 Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Latest 858 Therapeutics News
Apr 5, 2022
-- Jane Huang, M.D., appointed as independent director -- -- Sanjay Trehan joins as SVP of Business Development -- -- Gretchen Bain, Ph.D., promoted to SVP of Biology -- April 05, 2022 08:00 AM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )--858 Therapeutics today announced the strengthening of its board of directors and leadership team in preparation for its next stage of growth. To support the advancement of 858 Therapeutics’ portfolio of small molecule therapeutics directed against oncology targets, the company has named Jane Huang, M.D., as an independent director on the company’s Board. In addition, 858 Therapeutics has appointed Sanjay Trehan as SVP of Business Development and has promoted Gretchen Bain, Ph.D., to SVP of Biology. The company debuted in September 2021 with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital. Since inception, 858 Therapeutics has progressed multiple programs in novel areas of oncology and expects to start IND-enabling work on its lead development candidate during 2022 and to start clinical activities in 2023. Dr. Huang previously was Chief Medical Officer of Hematology at BeiGene Ltd. (NASDAQ:BGNE). Prior to joining BeiGene, Dr. Huang was the Vice President and Head of Development at Acerta Pharma, where she oversaw global clinical development of the BTK inhibitor, acalabrutinib. Previously, she served as Group Medical Director at Genentech, where she spent 10 years playing a leading role in drug development programs for several molecules at all stages of development, including venetoclax and obinutuzumab. She is also adjunct clinical faculty and an attending physician in Oncology at Stanford University. Mr. Trehan joins 858 Therapeutics from Genentech, where he served as Business Development Project Leader. Prior to joining Genentech, he held business development roles of increasing responsibility at Sanofi, including Director and Head of Business Development and Licensing for Rare Diseases. During his time at Sanofi and Genentech, Mr. Trehan successfully led the evaluation and execution of numerous transactions, including product licenses, co-developments, co-promotions, drug discovery collaborations and strategic alliances. Mr. Trehan received his MBA from the MIT Sloan School of Management. “We’re excited to welcome Jane to our board. She has extensive experience in oncology drug development, and her input on our clinical development strategy will be invaluable,” said Jeffrey Stafford, Ph.D., CEO of 858 Therapeutics. “Sanjay brings a high level of business development acumen to 858 and his expertise will be essential as we expand our portfolio and advance our programs towards the clinic. The additions of Jane and Sanjay represent our commitment to support the company’s next phase of development.” In addition to the board appointment of Dr. Huang and the hiring of Mr. Trehan, 858 Therapeutics has promoted Gretchen Bain, Ph.D., to SVP of Biology. Dr. Bain cofounded the company, initially serving as VP of Biology. Prior to 858 Therapeutics, Gretchen was VP of Biology at Jecure Therapeutics, a company that was acquired by Genentech in 2018 for its NLRP3 inflammasome inhibitor program. She began her career at Merck Research Labs and transitioned into biotech in 2005 as Executive Director of Biology at Amira Pharmaceuticals. At Amira, Gretchen contributed to the development of several clinical-stage small molecule therapeutics to treat inflammation and fibrosis and directed the efforts of the LPA1 receptor antagonist program that led to the acquisition of Amira by BMS. “Gretchen has been a key member of our senior management team from the company’s inception, and her promotion recognizes her numerous scientific contributions as well as her excellence in leading our biology efforts,” said Dr. Stafford. About 858 Therapeutics 858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule therapeutics directed against novel oncology targets. Its lead programs focus on the emerging fields of RNA modulation, innate immunity and synthetic lethality, and expand upon insights from over 10 years of work by the founders at predecessor companies. 858 is headquartered in the biotech hub of San Diego, CA, with operations also in New York City, providing proximity to leading investigators and scientific talent on both coasts of the U.S. For more information, please visit www.8five8tx.com . Contacts
858 Therapeutics Frequently Asked Questions (FAQ)
When was 858 Therapeutics founded?
858 Therapeutics was founded in 2019.
Where is 858 Therapeutics's headquarters?
858 Therapeutics's headquarters is located at 4757 Nexus Center Drive, San Diego.
What is 858 Therapeutics's latest funding round?
858 Therapeutics's latest funding round is Series A - III.
How much did 858 Therapeutics raise?
858 Therapeutics raised a total of $60M.
Who are the investors of 858 Therapeutics?
Investors of 858 Therapeutics include Versant Ventures, New Enterprise Associates, Cormorant Asset Management and Logos Capital.
Who are 858 Therapeutics's competitors?
Competitors of 858 Therapeutics include STORM Therapeutics.
Compare 858 Therapeutics to Competitors
Accent Therapeutics is a biopharmaceutical company that develops oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, the company aims to translate extraordinary science into life-changing therapies for patients.
STORM Therapeutics is a clinical biotechnology company creating therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. STORM has leveraged its first-mover advantage to establish a drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first-in-class small-molecule drug candidates for potential use in oncology, inflammation, viral infection, and CNS diseases. The company was founded in 2015 and is based in Cambridge, United Kingdom.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.